<DOC>
	<DOC>NCT00573638</DOC>
	<brief_summary>The study hypothesis is that the Xal-Ease with increase patient compliance with XALATAN</brief_summary>
	<brief_title>Effects of Xal-Ease on Patient Compliance With Xalatan</brief_title>
	<detailed_description />
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>40 to 80 years old Diagnosis warranting treatment with Xalatan eye drops. ambulatory and well functioning nonambulatory less than 40 or greater than 80 years old Not using Xalatan eye drops</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>glaucoma</keyword>
	<keyword>compliance</keyword>
	<keyword>eye drops</keyword>
	<keyword>deliver aid</keyword>
	<keyword>Patients could range anywhere from 40 to 80 years old</keyword>
	<keyword>Patients must have diagnosis requiring treatment with Xalatan.</keyword>
	<keyword>Patients will be male or female and from any racial/ethnic background.</keyword>
</DOC>